secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001628280-23-016620
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q1 net loss $61.7M; US product revenue +27% to $17M; Currax partnership
--------------------------------------------------------------------------------

- Total revenue $24.3M (+29% YoY); US net product revenue $17.0M (+27%); retail Rx equivalents +15% YoY.
- Net loss $61.7M vs $56.7M loss in Q1 2022; diluted EPS loss $0.79 vs $0.93.
- Pay-for-performance commercial partnership with Currax Pharmaceuticals to double promotional footprint.
- Regulatory filings for bempedoic acid label update expected in 1H 2023 in U.S. and Europe.
- Full-year 2023 operating expense guidance reaffirmed at $225-245M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/0001628280-23-016620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/espr-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-016620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer